Mankind Pharma In-Licenses Ensartinib from Betta Pharmaceuticals for India
Mankind Pharma enters into an exclusive in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a targeted therapy for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer.
In-licensing Agreement | 17/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy